Breaking Down the NDAA on the Making Medicine Podcast

Incubate executive director John Stanford recently discussed how Congress is reshaping biotechnology policy on an episode of the Making Medicine podcast.

The conversation focuses on the 2025 National Defense Authorization Act (NDAA), Congress's annual defense bill, and its emphasis on biotechnology as a national security priority. Stanford explains how the NDAA treats biotech as a strategic capability, with provisions that strengthen domestic biomanufacturing, supply chain resilience, data security, and laboratory infrastructure.

Stanford also breaks down new guardrails aimed at protecting the U.S. biotech ecosystem, particularly with respect to China. These include restrictions on contracting with certain biotech companies, increased scrutiny of partnerships and suppliers, and tighter screening on intelligence sharing and investment flows.

Beyond the NDAA, Stanford also covers a bipartisan proposal to create a government-backed investment fund focused on critical and emerging biotechnologies. The bill, the Independence Investment Fund Act, aims to help promising innovations bridge the "valley of death" between research and commercialization by de-risking early investments and making it easier for private capital to scale breakthrough technologies.

To hear John's full conversation, check out the Making Medicine podcast on YouTube, Spotify, or Apple Podcasts.